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ABSTRACT
Objective: To assess a questioneanswer pair (QAP)
database integrated with websites developed for drug
information centres to answer complex questions
effectively.
Design: Descriptive study with comparison of two
subsequent 6-year periods (1995e2000 and
2001e2006).
Setting: The Regional Medicines Information and
Pharmacovigilance Centres in Norway (RELIS).
Participants: A randomised sample of QAPs from the
RELIS database.
Primary outcome measure: Answer time in days
compared with ManneWhitney U test.
Secondary outcome measure: Number of drugs
involved (one, two, three or more), complexity
(judgemental and/or patient-related or not) and
literature search (none, simple or advanced) compared
with c
2 tests.
Results: 842 QAPs (312 from 1995 to 2000 and 530
from 2001 to 2006) were compared. The fraction of
judgemental and patient-related questions increased
(66%e75% and 54%e72%, respectively, p<0.01).
Number of drugs and literature search (>50%
advanced) was similar in the two periods, but the
fraction of answers referring to the RELIS
database increased (13%e31%, p<0.01). Median
answer time was reduced from 2 days to 1 (p<0.01),
although the fraction of complex questions increased
from the ﬁrst to the second period. Furthermore, the
mean number of questions per employee per year
increased from 66 to 89 from the ﬁrst to the second
period.
Conclusions: The authors conclude that RELIS has
a potential to efﬁciently answer complex questions.
The model is of relevance for organisation of drug
information centres.
INTRODUCTION
The regional medicines information and
pharmacovigilance centres (RELIS) were
established in 1995 with two regional centres.
Two additional centres were started in 1997
and 1998 with a ﬁfth added in 2001. Today,
RELIS is a national network made up of four
(two centres in Oslo became one in 2010)
drug information centres (DICs). They are
localised at regional university hospitals in
Norway, where pharmacists and clinical
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ARTICLE SUMMARY
Article focus
- A model with a national network of drug
information centres in Norway (RELIS) with
a common QAP database integrated with
websites has been developed.
- This article describes how the model makes it
possible to effectively answer complex
questions.
Key messages
- A randomised sample of QAPs from two
subsequent 6-year periods after RELIS started
in 1995 were analysed retrospectively.
- Comparison of the second to the ﬁrst period
shows RELIS’ potential to answer complex
questions with reduced answer time and
more frequent use of previous answers in the
database.
Strengths and limitations of this study
- A randomised sample from the two periods was
analysed.
- The study is descriptive, and analysis is
retrospective with poorly deﬁned variables.
- Development of RELIS (personnel and tech-
nology) as well as the internet during the total
study period suggests that interpretation of the
results should be performed with caution.
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Open Access Researchpharmacologists answer questions from healthcare
professionals. In 1995, RELIS started developing a full-
text questioneanswer pair (QAP) database through
cooperation with a software company (Arnett AS,
Bergen, Norway). The database was originally an internal
(not public) Microsoft Access application but was
converted to a web-based SQL database with separate
public (through the RELIS homepage) and internal
(through the RELIS intranet) interfaces in 2000e2001.
QAPs are indexed and published by the staff to be
searchable in Norwegian for healthcare professionals
free of charge through the public interface. QAPs
unsuitable for the public domain (eg, questions
answered solely by a copy of a previous answer, questions
which lack public interest and not associated with drugs
or questions that contain information that could identify
a patient through description of a rare disease) are
allocated to the internal interface (RELIS internal
database) only.
QAPs have been retrieved from the database through
a simple or advanced search function since 1995. Today,
the RELIS public database by default contains a simple
search function where a drug or text word (eg, hyper-
tension) is entered, but a more advanced search func-
tion with Boolean operators (AND/OR/NOT),
categories (eg, interactions, pregnancy), text word,
individual centre with question number is an option. In
the internal interface, the advanced search function is
default. The result of a search (eg, loratadine AND
pregnancy) is presented as a report of QAPs organised
chronologically (the newest on top). An individual QAP
in the report could contain a previous answer (in the
RELIS public database) as a linked reference available in
full text.
The websites include the RELIS homepage (http://
www.relis.no) targeted at healthcare professionals and
the RELIS intranet available for RELIS only. The
websites were developed in 2000, updated in 2010 and
represent the public and internal domain of the RELIS
network, respectively. On the homepage, RELIS publish
relevant drug information including relevant QAPs from
the database, announce meetings, present recent publi-
cations and describe news from the pharmacovigilance
work. Importantly, healthcare professionals can register
for a monthly newsletter (email) with selected drug
information from the homepage. The intranet functions
as a medium for all activity and cooperation between the
centres in Norway. Thus, it contains important docu-
ments, training and quality guidelines, discussions and
information to all employees. In addition it includes
dedicated sections for individual centres, common
working groups and projects.
In 1995 and up to 2006, the majority of questions to
RELIS were communicated through telephone followed
by email. However, in the last years, questions have been
mainly submitted through a web question form available
on the homepage. Healthcare professionals register
demographic data (occupation and working address),
the question (the patient being made anonymous) and
a deadline for the answer (answer time). Demographic
data are used for distribution of questions to the
respective centres, but all information in the web ques-
tion form are shared by all RELIS staff, regardless of
location, through exclusive emails. Other questions
(through telephone, fax, letters or ordinary email) not
submitted through the web-based question form have
still been shared by all staff since 1995 through an
‘answer in progress’ functionality in the RELIS internal
database. The name of the employee who received the
question and the one handling it is also registered. In
the case of particularly complex questions involving
several authors, co-signatures are used. In this way, the
handling of a question is fully traceable and answers to
subsequent similar questions can be based on re-use of
QAPs and communication with the authors.
Physicians consider the information provided by
RELIS in general and on drug use in pregnancy in
particular to be of high quality and of signiﬁcant clinical
impact.
1e3 Questions to the centres are mainly about
psychoactive drugs and adverse effects similar to other
DICs.
45Less is known about complexity of questions
and how this inﬂuences answer time. In the present
study, we retrospectively analysed a randomised sample
of QAPs in two time periods after RELIS started. The
objective was to examine if this model for DICs has
a potential to answer complex questions effectively.
METHODS
Contents of the RELIS database were analysed to illus-
trate how questions were answered. Two periods of
6 years were compared (1995e2000 and 2001e2006).
QAPs published in the public database in the respective
periods were used. They reﬂect the process of answering
better than QAPs unsuited for publication as described
above. Overall publication frequency in the period
(1995e2006) was 80% (range 66%e95% between indi-
vidual centres). Relevant data from QAPs, including
question number, were transferred to SPSS V.17.0 (SPSS
Inc.) for analysis and subjected to a randomisation
procedure in the application. From a total of 9697 QAPs,
a randomised sample of 963 QAPs was used for further
analysis. Each QAP was compared with the information
in the associated paper version (all documents and
information on answering the question) saved in the
respective RELIS centre. The paper version contained
the day the question was received and the corresponding
day an answer was provided. One hundred and twenty-
one QAPs were excluded because the questions
concerned nutritional or herbal medicine (n¼65), non-
medical products from pharmacies, homeopathy,
medical equipment, disinfection or chemicals (n¼26),
or questions that were answered solely by a previous
answer or by sending copies of relevant scientiﬁc articles
(n¼30). Exclusion of these QAPs was based on the
notion that DICs primary function and resources
(personnel and available drug information sources) are
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RELIS: a model for drug information centresdirected to answer questions concerning drugs. Thus,
based on a sequence of selection criteria (publication or
not, randomisation to 10% and the ﬁnal exclusion), 842
QAPs were included in the study. They were analysed for
the number of drugs involved in the question,
complexity, the type of literature search performed, use
of references (the number of references used and/or
use of the RELIS database as a reference) and the time
needed for providing an answer (in days). The number
of drugs involved in the queries were categorised as one,
two or three or more. Questions concerning groups of
drugs, for example, antipsychotics, were categorised as
three or more drugs. Judgemental and/or patient-
related questions were deﬁned as complex. Factual
questions, such as the therapeutic dose of a drug or its
half-life, can easily be located in textbooks, monographs
or databases. Judgemental questions require by deﬁni-
tion the integration of data or knowledge and experi-
ence in the process of making a decision regarding
a speciﬁc therapeutic problem.
6 The original deﬁnition
assumed that answers to judgemental questions could
not be given in any single reference source, but this
assumption has been excluded in the present and other
studies.
7 Judgemental questions are frequently patient-
related because they involve drug information applied to
a clinical situation associated with patient-speciﬁc char-
acteristics. They can, however, also represent a more
general drug-related problem. If the question was
answered without searching the literature and without
consulting colleagues, the literature search was cate-
gorised as none. If it was necessary to search the RELIS
database, databases containing monographs like the
Micromedex, the Summary of Product Characteristics
for the drug, reference books and/or colleagues/other
health professionals only, the search was categorised as
simple. If searches in databases like Medline, Embase or
Cochrane to obtain original articles were necessary, the
search was categorised as advanced. The number of
questions received each year were analysed by use of the
statistical function in the database. This function allows
RELIS to quantify the activity in the centres (eg, the
number of questions from physicians or pharmacists
from a particular county from a particular time period to
a particular RELIS can be retrieved). The number of
employees in the centres in the respective periods was
estimated but did not include all cases of maternity
leave, leave of absence and vacant positions. The mean
number of questions per employee per year was calcu-
lated from data corresponding to the start (year) and
end (year) of each period. Figure 1 summarises the
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Figure 1 Healthcare professionals with questions can search the Regional Medicines Information and Pharmacovigilance
Centres (RELIS) public database or submit a web question form through the RELIS homepage. The questions with deadline and
demographics are distributed to all RELIS staff, who have access to the questioneanswer pairs (QAPs) throughout their
processing in the RELIS internal domain. All QAPs are stored in the RELIS internal database and selected for publication in the
RELIS public database. A randomised sample of QAPs from 1995e2000 to 2001e2006 were retrospectively analysed and
compared with regard to number of drugs involved (one, two, three or more), complexity (judgemental and/or patient-related or
not), literature search (none, simple or advanced) and answer time (in days).
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RELIS: a model for drug information centrespresent RELIS model together with the study sample
and design.
Statistics
The data were analysed using SPSS V.17.0 (SPSS Inc).
Proportions between groups were analysed using c
2
comparisons. Discrete data between groups were
analysed using ManneWhitney U test. p Values <0.05
were considered signiﬁcant.
RESULTS
Table 1 shows characteristics of a randomised sample of
842 QAPs from 1995 to 2000 (n¼312) and 2001e2006
(n¼530), respectively, from the RELIS public database.
The mean number of questions per employee per year
increased from 66 to 89 from the ﬁrst to the second
period.
DISCUSSION
This paper describes a QAP database integrated with
websites for RELIS in Norway. The model is charac-
terised by a traceable answering process of questions
submitted to the centres, which are stored in full text in
a searchable database. Continuous growth of the data-
base makes it a valuable source of drug information for
healthcare professionals. Our analysis of two periods
after RELIS started demonstrates the potential of the
database to be an effective reference source through re-
use of previous answers. Furthermore, RELIS represents
a model for DICs where the staff efﬁciently answers
complex questions through cooperation in a network.
The RELIS model includes quality standards and in-
house training which ensures that the process of
answering questions is similar across the centres. The
intranet contains several guidelines on how to handle
QAPs (eg, how to write references, how to index in the
database). Furthermore, each centre uses the same
commercial drug information databases and textbooks as
sources. How to answer a question is discussed within
each RELIS by informal discussions or use of co-signa-
ture. It is also discussed between different centres due to
the transparency and traceability of the model and
regularly in the annual national meetings where all
centres participate. Thus, a person trained and located in
one centre can do work for a different centre through
this model in case of shortage of staff or increased
workload in one of the regions. In this way, the individual
centres are effective backups for each other. The ‘answer
in progress’ function facilitates communication about
new questions. Similar questions submitted simulta-
neously or subsequently can be answered based on
previous work and communication between individual
centres. In this way, unnecessary double work can be
reduced and complex questions asked frequently can be
answered within a short time frame.
Our data show that the re-use of the RELIS database as
a reference source in the answering of new questions was
signiﬁcantly higher in 2001e2006 than in 1995e2000.
This is not surprising, as the number of available QAPs in
the second time period was higher and the chance of
ﬁnding relevant information increases with the number
of questions received at RELIS. Re-use of the database as
a source of information is expected to decrease the
workload of repeated questions, but patient-speciﬁc
characteristics of relevance to the answer process still has
to be taken into account. Furthermore, complex ques-
tions not answered previously are associated with
increased workload. This is illustrated by the ﬁnding that
the average number of references in the QAPs did not
decrease from the ﬁrst to the second period and
advanced search strategies were still used in most cases.
We recently performed a prospective study where the
extent of literature search was the individual factor best
predicting the time spent answering questions in RELIS.
8
Table 1 Characteristics of a randomised sample of 842 questioneanswer pairs in the RELIS public database 1995e2006
Period 1995e2000 2001e2006 p Value
Questions, n 312 530
Drugs involved, category: % One: 49 One: 45 0.434x
Two: 19 Two: 22
Three or more: 32 Three or more: 34*
Judgemental questions, n (%) 207 (66) 399 (75) 0.005x
Patient-related questions, n (%) 170 (54) 379 (72) <0.001x
Answers, n 312 530
Literature search, type: %y None: 3 None: 2 0.315x
Simple: 43 Simple: 40
Advanced: 54 Advanced: 58
Reference to RELIS database, n (%) 39 (13) 164 (31) <0.001x
References, median (average) 3 (4) 4 (5) 0.100{
Days, median (average)z 2 (8.4) 1 (5.0) 0.001{
*The total number exceeds 100% because of rounding off to the nearest whole number.
ySimple literature search included monographs (eg, Martindale, Summary of Product Characteristics), advanced literature search included
articles (eg, databases like Medline and Embase).
zAnswer time is inﬂuenced by some extreme outliers (>100 days) and choice of deadline for answer (‘not important’ is an option).
xc
2 Test for contingency tables.
{ManneWhitney U test for two independent samples.
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RELIS: a model for drug information centresHowever, in RELIS, repeated questions are subjected to
a new literature search if 3 months have passed since
a previous answer was provided, and this was more likely
to happen in the period 1995e2006. With repeated
questions today, a previous answer in the database is
more likely to be updated and could be re-used. An
illustrating example is the common question of antide-
pressants and pregnancy, which is usually patient-related
and judgemental in its form. This type of question is
frequently submitted to RELIS because information in
product monographs is categorical and not useful for
solving a clinical situation with a depressed pregnant
patient in need of drug therapy. A recent answer from
the database with updated literature search can be
provided within much shorter time limits than would be
expected.
Interestingly, the answer time has been reported to be
the parameter associated with dissatisfaction with DICs
among physicians. A DIC in Denmark reported a median
time to answer (ﬁnal answer in contrast to preliminary
answer) of 25 days among satisﬁed physicians and 56 days
among unsatisﬁed physicians.
9 In our material, the
median time before a written answer was submitted to
the questioner was 2 days and 1 day in the periods
1995e2000 and 2001e2006, respectively. In the
subgroup of judgemental and patient-related QAPs, the
corresponding reduction was 4 to 2 days, and 2 to 1 day,
respectively (data not shown). The average number of
days before a written answer was given was reduced from
8 to 5 days in the two periods. These ﬁgures are inﬂu-
enced by a few extreme outliers (>100 days before an
answer were documented as given). Furthermore, ‘not
important’ is an option when healthcare professionals
specify their deadline for the answer. Some questions are
dependent on documentation from external sources (eg,
pharmaceutical industry) not controlled by RELIS. Thus,
the median number of days before an answer is given is
probably more representative for the service than the
average. However, the answer time depends greatly on
how fast the questioner needs his answer and how many
other questions that are received in the same time
period. Increased stafﬁng could also inﬂuence answer
time. However, our calculation of the mean number of
questions per employee per year does not account for all
the increase in activity during the period after RELIS
started. Several questions answered by telephone were
not documented in the database, and in 2003, the
centres increased the number of employees mainly to
handle adverse drug reaction reports due to new tasks
in pharmacovigilance. In the prospective study, we
measured the time spent to answer each of 96 questions.
8
The mean time needed to provide an answer was 4.0 h,
whereas the median time was 3.0 h (range 0.5e24 work
hours). This represents effective time, not the number of
workdays (including other work and lunch) recorded in
the present material. Interestingly, in the same study we
also observed a minor impact of the number of drugs on
answer time. This could be due to the experience that
questions about drug interactions are managed effec-
tively by use of drug interaction software.
8
The number of patient-related questions was signiﬁ-
cantly higher in the second time period than in the ﬁrst
one, as were the number of judgemental questions.
These two variables are related to each other in such
a way that patient-related questions often are associated
with judgemental considerations and vice versa. In the
present study, they were used to indicate complex
questions. In an earlier study, we found that more than
60% of the queries were judgemental and most of the
queries were patient-related.
8 The sample in that study
was much smaller compared with the present results, but
the numbers corresponds well. However, the assessment
of judgemental/non-judgemental is quite subjective,
and others have used the term consultative for questions
that requires clinical advice on a special case. Consulta-
tive questions usually entail discussion with the inquirer
on possible beneﬁts and hazards of one or more courses
of action in a clinical case.
10 The justiﬁcation for using
judgemental classiﬁcation versus consultative and other
classiﬁcations is not clear-cut, and this makes compari-
sons between different studies difﬁcult. However, DICs
in Norway are similar to the Swedish, which have
reported a particularly high proportion of consultative
queries.
11 During the history of RELIS, the number of
questions from physicians has steadily increased in
proportion to other groups of healthcare professionals.
In 2011, 65% of 2565 questions came from physicians
(40% of physicians from general practice), while 84%
were patient-related.
Adverse effects and pregnancy represent the two most
common categories of questions to RELIS and are
a substantial part of the QAP database. Feedback to
healthcare professionals who submit adverse drug reac-
tion reports commonly involve use of this database.
Furthermore, several reports were originally generated by
a question by a physician concerning possible adverse
effects. Thus, the database and the websites are strongly
integrated with the pharmacovigilance work. Our answers
have been evaluated to be of high quality and of signiﬁ-
cant clinical impact in several studies.
1e3 These studies
cover the period of 1995e1998 and 2006. Interestingly,
the study from 2006 concerned drug information in
pregnancy, which represents a category of questions
where re-use of information in the database is particularly
frequent.
3 However, such evaluations are performed by
a selected group of physicians and cannot be generalised
to other healthcare professionals. Although conse-
quences on a patient level are usually not known in these
results, a particularly relevant ﬁnding was that almost 10%
of physicians who evaluated the service reported that the
information prevented unnecessary termination of
ap r e g n a n c y .
3
The present model could be of international interest
for existing or planned network of DICs. A recent survey
of 75 DICs in the USA found an increase in the number
of complex questions in 70%, while 53% reported an
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RELIS: a model for drug information centresincrease in the time required to answer each question.
12
A shared database represents a useful tool for uniform
handling and documentation of complex questions.
Furthermore, it becomes an increasingly important drug
information source for healthcare professionals as well
as employees in the network. Through a solution with
web-based communication, the model could be of
particular importance in poor and undeveloped coun-
tries and continents with frequent epidemics, outbreaks
and health problems where rapid dissemination of drug
information is essential.
Conclusions
We conclude that RELIS represents a model with
a potential to efﬁciently answer complex questions. The
model is of relevance for organisation of DICs.
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